These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1391268)

  • 21. Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatment.
    Dani C; Ravasio R; Fioravanti L; Circelli M
    Ital J Pediatr; 2014 May; 40():40. PubMed ID: 24886906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corticosteroids and surfactant for prevention of neonatal RDS.
    Robertson B
    Ann Med; 1993 Jun; 25(3):285-8. PubMed ID: 8333929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
    Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
    J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antenatal corticosteroids promote survival of extremely preterm infants born at 22 to 23 weeks of gestation.
    Mori R; Kusuda S; Fujimura M;
    J Pediatr; 2011 Jul; 159(1):110-114.e1. PubMed ID: 21334006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early administration of the second surfactant dose in preterm infants with severe respiratory distress syndrome.
    Köksal N; Akpinar R; Cetinkaya M
    Turk J Pediatr; 2009; 51(6):556-64. PubMed ID: 20196389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Underdosing of Surfactant for Preterm Babies with Respiratory Distress Syndrome in Clinical Practice: A Retrospective Cohort Study.
    Boix H; Rite S; Arruza L; Fernandez C; Serrano I; Baquedano I; Sanchez A; Ferreira E; Fernandez P; Gonzalez R; Elorza MD
    Am J Perinatol; 2019 Jul; 36(9):943-948. PubMed ID: 30414597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antenatal corticosteroid therapy in premature infants.
    Smrcek JM; Schwartau N; Kohl M; Berg C; Geipel A; Krapp M; Diedrich K; Ludwig M
    Arch Gynecol Obstet; 2005 Jan; 271(1):26-32. PubMed ID: 15309401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morbidity and mortality of neonatal respiratory failure in China: surfactant treatment in very immature infants.
    Wang H; Gao X; Liu C; Yan C; Lin X; Yang C; Lin Z; Zhu W; Yang Z; Yu F; Qiu Y; Liu X; Zhou X; Chen C; Sun B;
    Pediatrics; 2012 Mar; 129(3):e731-40. PubMed ID: 22331337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms to explain surfactant responses.
    Jobe AH
    Biol Neonate; 2006; 89(4):298-302. PubMed ID: 16770069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Appropriateness of surfactant dosing for preterm babies with respiratory distress syndrome: retrospective cohort study.
    Jourdain G; Zacaria F; Ammar F; De Luca D
    Arch Dis Child Fetal Neonatal Ed; 2016 Mar; 101(2):F182-3. PubMed ID: 26785859
    [No Abstract]   [Full Text] [Related]  

  • 32. Perfusion index variability in preterm infants treated with two different natural surfactants for respiratory distress syndrome.
    Karadag N; Dilli D; Zenciroglu A; Aydin B; Beken S; Okumus N
    Am J Perinatol; 2014 Nov; 31(11):1015-22. PubMed ID: 24566756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antenatal corticosteroids beyond 34 weeks gestation: What do we do now?
    Kamath-Rayne BD; Rozance PJ; Goldenberg RL; Jobe AH
    Am J Obstet Gynecol; 2016 Oct; 215(4):423-30. PubMed ID: 27342043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effectiveness of surfactant replacement therapy for preterm infants with respiratory distress syndrome.
    Lim WL; Lim CT; Chye JK
    Med J Malaysia; 1998 Dec; 53(4):376-84. PubMed ID: 10971981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug utilisation in very preterm infants: any changes during the past decade?
    Lindner U; Hilgendorff A; Frey G; Gortner L
    Klin Padiatr; 2008; 220(4):238-42. PubMed ID: 18401813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surfactant replacement in preterm infants with respiratory distress syndrome.
    Dani C
    Acta Biomed; 2012; 83 Suppl 1():17-20. PubMed ID: 23029871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
    Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
    J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there a necessity for multiple doses of surfactant for respiratory distress syndrome of premature infants?
    Tsakalidis C; Giougki E; Karagianni P; Dokos C; Rallis D; Nikolaidis N
    Turk J Pediatr; 2012; 54(4):368-75. PubMed ID: 23692717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized trial.
    Egberts J; de Winter JP; Sedin G; de Kleine MJ; Broberger U; van Bel F; Curstedt T; Robertson B
    Pediatrics; 1993 Dec; 92(6):768-74. PubMed ID: 8233735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of surfactant and antenatal corticosteroid treatment on the pulmonary pathology of preterm infants with respiratory distress syndrome.
    Teksam O; Kale G
    Pathol Res Pract; 2009; 205(1):35-41. PubMed ID: 18951732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.